Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 476

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 476
---
 its website at www.aadibio.com, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Aadi electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Aadi are inactive textual references and except as specifically incorporated by reference into this proxy statement, information on those websites is not part of this proxy statement. Aadi has filed this proxy statement with the SEC, including the attached annexes, exhibits and schedules, which contains additional relevant information about Aadi and Aadi common stock. - 323 -

If you would like to request documents from Aadi, please send a request in writing or by
telephone at the following addresses:

Aadi Bioscience, Inc.

17383 Sunset Boulevard Suite A250

Pacific Palisades, California 90272

Attn: Corporate Secretary

Tel:
(424) 744-8055

Email: ir@aadibio.com

If you are an Aadi stockholder and would like additional copies, without charge, of this proxy statement or if you have questions about the
proposals contained herein, including the procedures for voting your shares, you should contact Aadi’s proxy solicitor, Sodali & Co, at the following address and telephone number:

SODALI & CO

430 Park Avenue,
14th Floor

New York, NY 10022

Email: AAADI@investor.sodali.com

Banks and Brokers Call: (203) 658-9400

Stockholders Call Toll Free: (800) 662-5200

- 324 -

AADI BIOSCIENCE, INC.’S FINANCIAL STATEMENTS Index to Financial Statements

| Audited Financial Statements for the Years Ended December 31, 2023 and 2022                   |     |      |
|:----------------------------------------------------------------------------------------------|:----|:-----|
| Report of Independent Registered Public Accounting Firm                                       |     | F-2  |
| Consolidated Balance Sheets as of December 31, 2023 and                                       
 2022                                                                                          |     | F-4  |
| Consolidated Statements of Operations and Comprehensive Loss for the Years ended              
 December 31, 2023 and 2022                                                                    |     | F-5  |
| Consolidated